NCT06778837

Brief Summary

The goal of this clinical trial in adult patients diagnosed with upper extremity lymphedema is to test the safety and effectiveness of small, wearable sensors that may be able to measure lymphedema. The main questions this study aims to answer are:

  • Do these sensors detect lymphedema?
  • If so, how accurate are these wearable sensors? Participants will complete one in-person measurement session and one phone call with study staff 14 days after the measurement session to check-in on the participant's well-being.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 2, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 16, 2025

Completed
11 days until next milestone

Study Start

First participant enrolled

January 27, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 3, 2025

Completed
11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 14, 2025

Completed
Last Updated

December 30, 2025

Status Verified

December 1, 2025

Enrollment Period

10 months

First QC Date

January 2, 2025

Last Update Submit

December 22, 2025

Conditions

Keywords

SensorDeviceLymphedemaUpper ExtremityWearableTissueHydrationStiffnessCancer

Outcome Measures

Primary Outcomes (2)

  • Tissue Hydration Score Recorded from the Tissue Hydration Sensor

    This score will determine whether or not fluid associated with lymphedema is detected when compared to previously validated measures (bioimpedance spectroscopy and tissue dielectric constant). This is a continuous ratio level of measurement.

    From enrollment to the end of the measurement session (appx. 3 hours)

  • Tissue Stiffness Score from the Tissue Stiffness Sensor

    This score will determine whether or not tissue affected by lymphedema can yield is detected when compared to a comparable clinical measurement device using Young's Modulus. This is a continuous ratio level of measurement.

    From enrollment to the end of the measurement session (appx. 3 hours)

Secondary Outcomes (3)

  • Bioimpedance spectroscopy (BIS) L-Dex score

    Three hours

  • Tissue Dielectric Constant (TDC)

    From enrollment to the end of the measurement session (appx. 3 hours)

  • Volume of the Upper Extremities

    Three hours

Study Arms (1)

All Participants

Device: Wearable devices to detect lymphedema

Interventions

All participants will undergo measurement of the upper extremities to test the validity and safety of wearable sensors to measure lymphedema.

All Participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will recruit patients using the above specified criteria in the Chicagoland area.

You may qualify if:

  • Patients with a diagnosis of unilateral lymphedema that affects the upper extremity (UE).
  • Patients previously diagnosed with non-metastatic cancer.
  • Adults 18 years of age and older.

You may not qualify if:

  • Patients with history of lymphatic surgery.
  • Patients with implantable devices (e.g., pacemaker, pacemaker/defibrillator, intrathecal pump, joint replacements, etc.) or any other device deemed unsafe by the treating investigator.
  • Patients with an amputation involving the upper extremity.
  • Patients with known allergies to adhesives - including silicone adhesives.
  • Patients with the following comorbidities: diabetes, congestive heart failure, peripheral vascular disease, irradiated upper extremity skin, psoriasis, atopic dermatitis, open wounds/skin breakdown.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

LymphedemaNeoplasms

Condition Hierarchy (Ancestors)

Lymphatic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Target Duration
2 Weeks
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor at Northwestern University, Department of Physical Therapy and Human Movement Sciences, Director of Cancer Rehabilitation Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Director of Cancer Rehabilitation Stud

Study Record Dates

First Submitted

January 2, 2025

First Posted

January 16, 2025

Study Start

January 27, 2025

Primary Completion

December 3, 2025

Study Completion

December 14, 2025

Last Updated

December 30, 2025

Record last verified: 2025-12

Locations